Skindex-29
Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.
Allikakirje
Tsiteeringud kopeeritud meetodi allikakirjest sõna-sõnalt. Nendest ei saa järeldada väidete tasemel kinnitust.
- Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. · DOI 10.1111/1523-1747.ep12365600
- Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440. · DOI 10.1001/archderm.133.11.1433
Kureeritud väited
Väited on salvestatud tõendite registrisse, igal oma hinnanguga.
See vaade ei loo väite hinnangut, kui registris seda pole.
Seotud meetodid
Genereeritud meetodigraafist ja kuvatud masina soovitatud seostena – väiteid ei järeldata.